Advertisement
RHHBY Novinky na Forexu
Roche To Invest $50 Bln In U.S; To Create 12,000 Jobs
Amid the ongoing tariff issues, Swiss drug major Roche Holding AG announced its plan to invest $50 billion in the United States in the next five years, aiming to expand its Pharmaceutical and Diagnostics Divisions. With all new and expanded manufacturing capacity, Roche aims to export more medicines from the US than it imports.
RTTNews
|
Před 19 dny
Roche Q1 Sales Down, Confirms FY24 View; Stock Down
Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.
RTTNews
|
Před 383 dny
It's A First; Cellular Therapy For Melanoma And Drug To Reduce Food Allergic Reactions Get FDA Nod
Latest approvals by the U.S. Food and Drug Administration include Iovance Biotherapeutics Inc.'s Amtagvi - the first cellular therapy indicated for the treatment of unresectable or metastatic melanoma, as well as Genentech's Xolair- the first medication to help reduce allergic reactions to multiple foods after accidental exposure.
RTTNews
|
Před 447 dny
ShapeTX Expands Ongoing Collaboration With Roche
ShapeTX announced Thursday the expansion of its partnership with Roche Holding AG (RHHBY.PK), with Roche adding a new target to their ongoing collaboration, which was initially established in August 2021.
RTTNews
|
Před 529 dny
Monte Rosa Therapeutics Inks Strategic Collaboration With Roche To Develop Molecular Glue Degraders
Biotechnology company Monte Rosa Therapeutics, Inc. (GLUE) announced Tuesday it has entered into a strategic collaboration and licensing agreement with Roche Holding AG to discover and develop MGDs against targets in cancer and neurological diseases.
RTTNews
|
Před 573 dny
Genentech Announces New Data From Phase II FENopta Study Of Fenebrutinib For People With RMS
Genentech, Inc., a subsidiary of the Roche Group (RHHBY.PK) announced Friday new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS). The data has a consistent safety profile to other fenebrutinib trials.
RTTNews
|
Před 577 dny
Roche Says FDA Clears Additional Alzheimer's Disease Cerebrospinal Fluid Assays
Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that its Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.
RTTNews
|
Před 685 dny
SD Biosensor Recalls Certain COVID-19 At-Home Tests Distributed By Roche
Seoul, South Korea -based SD Biosensor, Inc. has recalled specific Pilot COVID-19 At-Home Tests, distributed by Roche Diagnostics in the United States, citing potential microbial contamination in the liquid buffer solution, the U.S. Food and Drug Administration said. The Pilot COVID-19 At-Home Test is an over-the-counter rapid antigen test and uses a nasal swab sample that can be self-collected...
RTTNews
|
Před 735 dny
